TG Therapeutics, Inc. (TGTX) Misses Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TG Therapeutics, Inc. Announces First Quarter 2014 Financial Results and Business Update
May 12, 2014 4:30 PM EDTNEW YORK, May 12, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq: TGTX), an innovative clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs, today announced its results for the first quarter ended March 31, 2014 and recent company developments.
Financial Results for the First Quarter 2014
At March 31, 2014 the Company had cash, cash equivalents, investment securities, and interest receivable of $54.5 million, as compared to $45.4 million at December 31, 2013.
The consolidated net loss for the first quarter ended March 31,... More
